Study participants and clinical outcomes
| Total | % | |
|---|---|---|
| Study participants | ||
| Invited | 66 225 | |
| Kits returned | 40 125 | 60.6 |
| Testable | 38 720 | 58.5 |
| Positive (f-Hb concentration ≥400 ng/ml) | 943 | 2.4 |
| Undergoing colonoscopy | 814 | 86.3 |
| Declined colonoscopy/unfit | 129 | 13.7 |
| Clinical outcomes | ||
| Neoplasia detected | 350 | 43 |
| Cancer | 39 | 4.8 |
| Adenoma | 311 | 38.2 |
| High-risk adenoma | 190 | 23.3 |
| Low-risk adenoma | 119 | 14.6 |
| Unclassified risk adenoma | 2 | 0.2 |
| Hyperplastic polyps | 40 | 4.9 |
| Inflammatory bowel disease | 34 | 4.2 |
| Diverticular disease | 104 | 12.8 |
| Haemorrhoids | 48 | 5.9 |
| Miscellaneous pathology* | 67 | 8.2 |
| No pathology | 171† | 21 |
*Miscellaneous pathology includes angiodysplasia, mucosal prolapse and those who had two or more non-neoplastic outcomes occurring synchronously.
†One participant with no pathology detected did not have a definitive f-Hb result and was therefore excluded from analysis from this point onwards.
f-Hb, faecal haemoglobin concentration.